Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma.

Autor: Stauffer S; Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute, NIH, 8560 Progress Drive, Frederick, MD 21701, USA., Roth JS; Early Translation Branch, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, 9800 Medical Center Drive, Rockville, MD 20850, USA., Hernandez ER; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA., Kowalczyk JT; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA., Sealover NE; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Services, Bethesda, MD 20814, USA., Hebron KE; Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute, NIH, 8560 Progress Drive, Frederick, MD 21701, USA., James A; Animal Research Technical Support, Laboratory Animal Sciences Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA., Isanogle KA; Animal Research Technical Support, Laboratory Animal Sciences Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA., Riffle LA; Small Animal Imaging Program, Laboratory Animal Sciences Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA., Ileva L; Small Animal Imaging Program, Laboratory Animal Sciences Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA., Luo X; Collaborative Protein Technology Resource, National Cancer Institute, NIH, Bethesda, MD 20892, USA., Chen JQ; Collaborative Protein Technology Resource, National Cancer Institute, NIH, Bethesda, MD 20892, USA., Kedei N; Collaborative Protein Technology Resource, National Cancer Institute, NIH, Bethesda, MD 20892, USA., Kortum RL; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Services, Bethesda, MD 20814, USA., Lei H; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA., Shern JF; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA., Kalen JD; Small Animal Imaging Program, Laboratory Animal Sciences Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA., Edmondson EF; Molecular Histopathology Laboratory, Laboratory Animal Sciences Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA., Hall MD; Early Translation Branch, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, 9800 Medical Center Drive, Rockville, MD 20850, USA., Difilippantonio S; Animal Research Technical Support, Laboratory Animal Sciences Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA., Thiele CJ; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA., Yohe ME; Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute, NIH, 8560 Progress Drive, Frederick, MD 21701, USA.; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA.

Publikováno v: Cancers [Cancers (Basel)] 2024 Jun 25; Vol. 16 (13). Date of Electronic Publication: 2024 Jun 25.

KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma.

Autor: Kim YY; Genetics Branch, NCI, NIH, Bethesda, MD, USA. yong.kim@nih.gov., Gryder BE; Genetics Branch, NCI, NIH, Bethesda, MD, USA.; Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, USA., Sinniah R; Genetics Branch, NCI, NIH, Bethesda, MD, USA., Peach ML; Basic Science Program, Frederick National Laboratory for Cancer Research (FNLCR), Frederick, MD, USA., Shern JF; Pediatric Oncology Branch, NCI, NIH, Bethesda, MD, USA., Abdelmaksoud A; Collaborative Bioinformatics Resource, NCI, NIH, Bethesda, MD, USA., Pomella S; Genetics Branch, NCI, NIH, Bethesda, MD, USA.; Department of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy., Woldemichael GM; Leidos Biomed Res Inc, FNLCR, Basic Sci Program, Frederick, MD, USA.; Molecular Targets Program, NCI, NIH, Frederick, MD, USA., Stanton BZ; Genetics Branch, NCI, NIH, Bethesda, MD, USA.; Nationwide Children's Hospital, Center for Childhood Cancer Research, Columbus, OH, USA.; Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA.; Department of Biological Chemistry & Pharmacology, The Ohio State University College of Medicine, Columbus, OH, USA., Milewski D; Genetics Branch, NCI, NIH, Bethesda, MD, USA., Barchi JJ Jr; Chemical Biology Laboratory, NCI, NIH, Frederick, MD, USA., Schneekloth JS Jr; Chemical Biology Laboratory, NCI, NIH, Frederick, MD, USA., Chari R; Genome Modification Core, Laboratory Animal Sciences Program, FNLCR, Frederick, MD, USA., Kowalczyk JT; Genetics Branch, NCI, NIH, Bethesda, MD, USA., Shenoy SR; Leidos Biomed Res Inc, FNLCR, Basic Sci Program, Frederick, MD, USA.; Molecular Targets Program, NCI, NIH, Frederick, MD, USA., Evans JR; Natural Products Branch, NCI, NIH, Frederick, MD, USA., Song YK; Genetics Branch, NCI, NIH, Bethesda, MD, USA., Wang C; Genetics Branch, NCI, NIH, Bethesda, MD, USA., Wen X; Genetics Branch, NCI, NIH, Bethesda, MD, USA., Chou HC; Genetics Branch, NCI, NIH, Bethesda, MD, USA., Gangalapudi V; Genetics Branch, NCI, NIH, Bethesda, MD, USA., Esposito D; Protein Expression Laboratory, FNLCR, NIH, Frederick, MD, USA., Jones J; Protein Expression Laboratory, FNLCR, NIH, Frederick, MD, USA., Procter L; Protein Expression Laboratory, FNLCR, NIH, Frederick, MD, USA., O'Neill M; Protein Characterization Laboratory, FNLCR, NIH, Frederick, MD, USA., Jenkins LM; Laboratory of Cell Biology, NCI, NIH, Bethesda, MD, USA., Tarasova NI; Cancer Innovation Laboratory, NCI, NIH, Bethesda, MD, USA., Wei JS; Genetics Branch, NCI, NIH, Bethesda, MD, USA., McMahon JB; Molecular Targets Program, NCI, NIH, Frederick, MD, USA., O'Keefe BR; Molecular Targets Program, NCI, NIH, Frederick, MD, USA.; Natural Products Branch, NCI, NIH, Frederick, MD, USA., Hawley RG; Genetics Branch, NCI, NIH, Bethesda, MD, USA.; Department of Anatomy and Cell Biology, George Washington University, Washington, DC, USA., Khan J; Genetics Branch, NCI, NIH, Bethesda, MD, USA. khanjav@mail.nih.gov.

Publikováno v: Nature communications [Nat Commun] 2024 Feb 24; Vol. 15 (1), pp. 1703. Date of Electronic Publication: 2024 Feb 24.

Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies.

Autor: Kowalczyk JT; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Fabian KP; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Padget MR; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Lopez DC; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Hoke AT; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Allen CT; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Hermsen M; Department Head and Neck Cancer, Centro de Investigación Biomédica en Red, Madrid, Spain., London NR Jr; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.; Sinonasal and Skull Base Tumor Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, USA.; Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Hodge JW; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA jh241d@nih.gov.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Dec; Vol. 10 (12).

Multi-spectral immunofluorescence evaluation of the myeloid, T cell, and natural killer cell tumor immune microenvironment in chordoma may guide immunotherapeutic strategies.

Autor: Lopez DC; Sinonasal and Skull Base Tumor Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, United States.; Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, United States., Robbins YL; Section on Translational Tumor Immunology, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, United States., Kowalczyk JT; Center for Immuno-Oncology, National Cancer Institute, Center for Cancer Research, National Institutes of Health (CCR, NIH), Bethesda, MD, United States., Lassoued W; Center for Immuno-Oncology, National Cancer Institute, Center for Cancer Research, National Institutes of Health (CCR, NIH), Bethesda, MD, United States., Gulley JL; Center for Immuno-Oncology, National Cancer Institute, Center for Cancer Research, National Institutes of Health (CCR, NIH), Bethesda, MD, United States., Miettinen MM; Laboratory for Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States., Gallia GL; Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Allen CT; Section on Translational Tumor Immunology, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, United States., Hodge JW; Center for Immuno-Oncology, National Cancer Institute, Center for Cancer Research, National Institutes of Health (CCR, NIH), Bethesda, MD, United States., London NR Jr; Sinonasal and Skull Base Tumor Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, United States.; Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Publikováno v: Frontiers in oncology [Front Oncol] 2022 Oct 21; Vol. 12, pp. 1012058. Date of Electronic Publication: 2022 Oct 21 (Print Publication: 2022).